DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "steatohepatitis"


2 mentions found


☆ A tiny biotech's experimental treatment for a silent disease that strikes millions just cleared a key hurdle and the stock is up more than 200%
  + stars: | 2022-12-19 | by ( Sarah Braner | ) www.businessinsider.com   time to read: +2 min
Madrigal Pharmaceuticals reported positive results in its phase 3 trial for a drug to treat NASH. NASH is a serious liver condition that does not have an FDA-approved treatment. Many people don't even know they have it, which is why some people call it a "silent" disease. In a trial of more than 950 patients, 26% of patients taking 80mg and 30% of patients taking 100mg of the drug showed that NASH activity like swelling had been reduced. Pharma hasn't found a way to treat NASH yetThe pharma industry has been watching NASH for a while.
☆ A Chronic Disease Still Waiting for a Drug
  + stars: | 2022-09-20 | by ( David Wainer | ) www.wsj.com   time to read: +1 min
Drug companies have developed treatments for some of the rarest diseases afflicting a tiny percentage of the population, yet they have failed repeatedly to get a drug on the market for a chronic and increasingly common one. As biotech companies take new shots on goal for the liver disease known as NASH, or nonalcoholic steatohepatitis, investors are understandably reluctant after being burned repeatedly. Take Intercept Pharmaceuticals which at the height of the Wall Street excitement over NASH treatments fetched as much as $462 a share. The stock has since plunged, trading now at just over $17, erasing $6 billion in market value. The biotech’s drug for NASH was rejected by the U.S. Food and Drug Administration in 2020 because of safety concerns, but Intercept is trying again.
<< prev 1 next >>
Total: 2